Friday, 12 October 2007
12:50
Welcome
and introduction
John S. Oxford, PhD and Raul Ortiz de Lejarazu,
MD, PhD
Session I: Influenza A and B, present and future implications
13:00
State
of the art presentation on influenza A and B
Albert
D. Osterhaus, PhD, DVM
13:30
Estimates
of incidence of interpandemic influenza in Europe, driving factors including
global travel
Angus
Nicoll, CBE
14:00
Medical
and financial burden of influenza
Thomas
D. Szucs, MD, MPH, MBA
14:30
Diagnosis
of influenza
Maria
C. Zambon, MD
15:00
Break
Session II: Keynote lecture
15:30
Neuraminidase
and its role in treatment of influenza
W. Graeme Laver, PhD, FRS
Session III: Approaches to the prevention influenza
16:10
Comparison
of live and attenuated vaccines in influenza
Arnold
S. Monto, MD
16:30
Seasonal
prophylaxis with antivirals
Allison
J. McGeer, MD, FRCPC
16:50
New
vaccine approaches for seasonal and pandemic influenza
Abraham
M. Palache, PhD, MSc
17:10
New
adjuvant based approaches to influenza prevention
Karl
G. Nicholson, MD
17:30
Summary
and adjourn
Arnold
S. Monto, MD
Saturday, 13 October 2007
8:00
Introduction
Arnold S. Monto, MD, and Raul Ortiz de Lejarazu, MD, PhD
Session IV: Influenza infection and the patient
8:10
Influenza
infection and the “normal patient”
Werner Lange, MD
8:30
Influenza
infection and the high risk patient (including the elderly)
Laurent Kaiser, MD
8:50
Influenza
infection and the pediatric patient
Terho
Heikkinen, MD, PhD
9:10
Effect
of infection within the family unit
Douglas
Fleming, MB, PhD, FMedSci
9:30
Break
Session V: Management of influenza virus infection
10:00
Overview
of antivirals
Fred Y. Aoki, MD, FRCPC
10:20
Case
management of your patient
Iain Stephenson, MRCP
10:40
New
data on reduced risk of mortality with oseltamivir
Allison J. McGeer, MD, FRCPC
11:00
Panel
discussion: Barriers to treatment (self-limiting disease, cost, perceived
efficacy, resistance, “reserve it”)
John S. Oxford, PhD
Fred Y. Aoki, MD, FRCPC
Alan J. Hay, PhD
Raul Ortiz de Lejarazu, MD, PhD
Arnold S. Monto, MD
Karl G. Nicholson, MD
11:40
Better
benefits with faster use: Importance of spread of access to therapies
Fred Y. Aoki, MD, FRCPC
11:55
Drug
resistance
Alan J. Hay, PhD
| 12:10 Lunch symposium Pandemic influenza: From plans to practicalities Supported by Roche |
Session VI: Keynote lecture
14:00
Future
planning for pandemic influenza
Bruno
Lina, MD
Session VII: Post-exposure prophylaxis of influenza virus
14:40
Overview
of post exposure prophylaxis
Arnold
S. Monto, MD
15:00
Panel
discussion: Post exposure prophylaxis (role of therapy, transmission
from primary, health economics)
John S. Oxford, PhD
Arnold S. Monto, MD
Raul Ortiz de Lejarazu, MD, PhD
16:00
Break
Session VIII: Therapeutic approaches to your patient: A case based discussion
16:30
Therapeutic
approaches to the pediatric patient
Karl G. Nicholson, MD
16:50
Therapeutic
approaches to the geriatric patient
Arnold S. Monto, MD
17:10
Therapeutic
approaches to the family unit
Douglas Fleming, MB, PhD, FMedSci
17:30
Therapeutic
approaches to the institutionalized patient
Bernhard R. Ruf, MD
17:50
Summary
and adjourn
John S. Oxford, PhD
Sunday, 14 October 2007
9:00
Welcome
and introduction
Arnold
S. Monto, MD
Session IX: Future therapeutic approaches to influenza virus
9:10
Protecting
virus RNA: A new concept in influenza antivirals
Nigel J. Dimmock
9:30
New
approaches to antiviral therapy
Noel
A. Roberts
9:50
International
challenges in pandemic vaccine development
John
Wood, PhD
10:10
Pandemic
vaccination approaches
David
Fedson, MD
Session X: Keynote lecture
10:30
Working
on the front line with H5N1
Abdel-Nasser, MD
11:00
Panel
Discussion
11:30
Summary
and adjourn
Arnold S. Monto, MD and John S. Oxford, PhD
©2007 Imedex®, Inc. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.